Stella Diagnostics (Stella Diagnostics) Change In Receivables : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Change In Receivables?

Stella Diagnostics's change in receivables for the quarter that ended in Sep. 2023 was $0.00 Mil. It means Stella Diagnostics's Accounts Receivable stayed the same from Sep. 2022 to Sep. 2023 .

Stella Diagnostics's change in receivables for the fiscal year that ended in . 20 was $0.00 Mil. It means Stella Diagnostics's Accounts Receivable stayed the same from . 20 to . 20 .

Stella Diagnostics's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Stella Diagnostics's liquidation value for the three months ended in Sep. 2023 was $-16.86 Mil.

Stella Diagnostics Change In Receivables Historical Data

The historical data trend for Stella Diagnostics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Change In Receivables Chart

Stella Diagnostics Annual Data

Trend

Change In Receivables

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Change In Receivables	-	-

Stella Diagnostics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Stella Diagnostics (OTCPK:SLDX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Stella Diagnostics's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Stella Diagnostics's accounts receivable are only considered to be worth 75% of book value:

Stella Diagnostics's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.002	-	16.864	+	0.75 * 0	+	0.5 * 0
=	-16.86

Stella Diagnostics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.